Short and Long-Term Effects of Cannabis on Symptoms of Post-Traumatic Stress Disorder.
Emily M LaFrance, Nicholas C. Glodosky, Marcel O Bonn-Miller, Carrie Cuttler
Journal of Affective Disorders September 1, 2020 DOI: 10.1016/j.jad.2020.05.132 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Observational study using self-reported app data (latent change score and multilevel models) Peer reviewed |
|---|---|
| Sample size | 404 |
| Population | Self-identified medical cannabis users with PTSD who used the Strainprint app |
| Duration | 31 months |
| Topics | Anxiety Cannabis PTSD |
| Keywords | Flashbacks Intrusions Irritability |
| Key findings | Cannabis use was followed by immediate reductions of more than 50% in intrusive thoughts, flashbacks, irritability, and anxiety. Higher doses predicted larger reductions in intrusions and anxiety, and dose for anxiety rose over time. Because baseline symptom severity remained constant and anxiety dose escalated, the authors suggest cannabis may not be an effective long-term remedy, possibly due to tolerance. |
Abstract
Many individuals use cannabis to manage symptoms of post-traumatic stress disorder (PTSD), and evidence indicates that the endocannabinoid system represents a viable target for treating these symptoms. Data from 404 medical cannabis users who self-identified as having PTSD were obtained from Strainprint®, a medical cannabis app that patients use to track changes in symptoms as a function of different strains and doses of cannabis across time. This sample collectively used the app 11,797 times over 31 months to track PTSD-related symptoms (intrusive thoughts, flashbacks, irritability, and/or anxiety) immediately before and after inhaling cannabis. Latent change score models were used to examine changes in symptom severity and predictors of these changes (gender, dose, cannabis constituents, time). Multilevel models were used to explore long-term consequences of repeatedly using cannabis to manage these symptoms. All symptoms were reduced by more than 50% immediately after cannabis use. Time predicted larger decreases in intrusions and irritability, with later cannabis use sessions predicting greater symptom relief than earlier sessions. Higher doses of cannabis predicted larger reductions in intrusions and anxiety, and dose used to treat anxiety increased over time. Baseline severity of all symptoms remained constant across time. The sample was self-selected, self-identified as having PTSD, and there was no placebo control group. Cannabis provides temporary relief from PTSD-related symptoms. However, it may not be an effective long-term remedy as baseline symptoms were maintained over time and dose used for anxiety increased over time, which is indicative of development of tolerance.
Comparable studies
Other observational and cohort studies on cannabis for anxiety, most cited first.
Citations in the library
Cited by 6
- The short-term impact of 3 smoked cannabis preparations versus placebo on PTSD symptoms: A randomized cross-over clinical trial PLoS One March 17, 2021
- Assessment of clinical outcomes in patients with post-traumatic stress disorder: analysis from the UK Medical Cannabis Registry. Expert Review of Neurotherapeutics 2022
- High-Concentration Delta-9-Tetrahydrocannabinol Cannabis Products and Mental Health Outcomes : A Systematic Review. Annals of Internal Medicine October 1, 2025
- Challenges and considerations for treating PTSD with medicinal cannabis: the Australian clinician's perspective. Expert Review of Clinical Pharmacology 2023
- Cannabis and cannabinoids for the treatment of mental and substance use disorders and symptoms: A systematic review and meta-analysis of experimental and observational studies. Psychiatry Research August 1, 2026
and 1 more in the library
Cites 3
- Use and effects of cannabinoids in military veterans with posttraumatic stress disorder. American Journal of Health-System Pharmacy August 1, 2015
- The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: A preliminary randomized, double-blind, placebo-controlled cross-over design study. Psychoneuroendocrinology January 2015
- Use of a synthetic cannabinoid in a correctional population for posttraumatic stress disorder-related insomnia and nightmares, chronic pain, harm reduction, and other indications: a retrospective evaluation. Journal of Clinical Psychopharmacology October 2014